With official shortages ended, but the first generics gearing up for launch, companies are looking for the next generation of ...
Novo and Lilly’s campaigns are not limited to advertisements alone, and both companies are trying to raise awareness around obesity through research studies and conferences.
Citi reiterated a Buy rating and $1,190 price target on Eli Lilly (LLY), saying the firm expects a positive read-through to the shares on FDA’s ...
FDA is aware that some patients and health care professionals may look to unapproved versions of GLP-1 – glucagon-like peptide-1 receptor agonists – drugs, including semaglutide and tirzepatide, as an ...
A rise in the use of non-FDA-approved diabetes and obesity medications has spurred health care professionals and medical ...
People without diabetes can lose up to 13% of their starting weight in 6 months using tirzepatide (Mounjaro) as an off-label ...
We recently published a list of 12 Best Quality Stocks to Invest in Now. In this article, we are going to take a look at ...
Tirzepatide and Semaglutide Improve Weight Loss, Cardiovascular Conditions, but Deemed Too Expensive
Weight loss drugs like tirzepatide and semaglutide are growing in popularity and offer significant health benefits, but they ...
Semaglutide and tirzepatide confer greater improvements in life expectancy than naltrexone/bupropion and ...
In their own responses to the senators’ inquiries last fall, both Pfizer and Lilly emphasized the independence of their ...
After years of weight loss drug shortages, the FDA is saying there’s now an adequate supply for most medications and they ...
AbbVie Inc. enters the obesity market with GUBamy, a promising amylin analog. Click here to find out why ABBV stock is a Buy.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback